NCT05350202

Emp-Activity: Empagliflozin Functional Capacity

Empagliflozin Functional Capacity - Non-Interventional Study

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 3,431 (actual)
• Sponsor: Boehringer Ingelheim · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a multinational non-interventional study based on newly collected data to assess demographics, disease, and treatment pattern of patients with chronic Heart Failure (HF) in a two-cohort design: one cohort will receive first prescription of empagliflozin as routine therapy for HF, the other cohort will receive HF therapy with drugs with another mechanism of action. Treatment of HF according to routine practice is determined by the physician independent of the participation of the patient in this non-interventional study.

Conditions

• Heart Failure

Interventions

Type	Name	Description
DRUG	Empagliflozin	Empagliflozin was administered according to the approved product information.

Timeline

• Start date: 2022-12-18
• Primary completion: 2024-07-25
• Completion: 2024-07-25
• First posted: 2022-04-28
• Last updated: 2025-08-26
• Results posted: 2025-08-26

Locations

350 sites across 6 countries: Bulgaria, Czechia, Hungary, Poland, Romania, Switzerland